57718-47-5

Usage

Uses

Used in Pharmaceutical Industry:
N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE is used as a key intermediate in the synthesis of various drug candidates due to its unique chemical structure and potential pharmacological activities.
Used in Antihistamine Development:
N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE is utilized as a precursor in the development of antihistamine agents, aiming to alleviate symptoms associated with allergic reactions.
Used in Antipsychotic Drug Research:
N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE is employed as a starting material in the research and development of antipsychotic drugs, targeting the treatment of mental health disorders such as schizophrenia and bipolar disorder.
Used in Neurodegenerative Disorder Treatment:
N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE is studied for its potential role in the treatment of neurodegenerative disorders, including Parkinson's disease, with the aim of providing therapeutic benefits to patients suffering from these conditions.

InChI:InChI=1/C18H23N3/c19-17-8-4-5-9-18(17)20-16-10-12-21(13-11-16)14-15-6-2-1-3-7-15/h1-9,16,20H,10-14,19H2

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 95-54-5 1,2-diamino-benzene 
• 1493-27-2 ortho-nitrofluorobenzene 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 7255-89-2 (1-Benzyl-piperidin-4-yl)-(2-nitro-phenyl)-amine 

Downstream Products

• 84176-75-0 1-(1-Benzyl-4-piperidinyl)-1H-benzimidazole 
• 1096357-14-0 C₂₃H₂₇N₃O₂ 
• 83763-11-5 1-piperidine-4-yl-1H-benzimidazole 
• 301220-17-7 α-(R)-(3-(S)-((4-Benzoimidazol-1-yl-piperidin-1-yl)methyl)4-(S)-phenyl-pyrrolidin-1-yl)-cyclohexaneacetic acid, 4-methoxy-benzyl ester 

Relevant academic research and scientific papers

SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS

The invention provides modulators of the nociceptin receptor (NOP), including both agonists and antagonists. A compound of the invention can be a selective modulator of NOP with respect to the μ- and κ- opioid receptors (MOP and KOP), thus providing a therapeutic method for the treatment of conditions wherein selective NOP modulation is medically indicated and MOP or KOP modulation may be less desirable. A compound of the invention can be a NOP full agonist, partial agonist, inverse agonist, positive or negative allosteric modulator, or a functionally biased agonist. A compound of the invention can be used for the treatment of an anxiety state, post-traumatic stress disorder, addictive disorders (including overuse of alcohol, tobacco, and drugs of abuse such as cocaine, amphetamines, and opitates), misregulated food intake and/or energy expenditure, cough, sleep disorders, migraine, pain, depression, or neurodegenerative disorders such as Parkinsons disease or Alzheimers disease.

Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: Effects of fused heterocycles on antiviral activity and pharmacokinetic properties

A series of 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists containing a variety of fused heterocycles at the 4-position of the piperidine side chain has been discovered, which are orally bioavailable with potent anti-HIV activity.

From hit to lead. Combining two complementary methods for focused library design. Application to μ opiate ligands

Compound 1 obtained by random screening and displaying a micromolar activity on the μ opiate receptor was chosen as a starting point for optimization. Two complementary concepts of similarity were used for the design of analogues and compared. These are based, respectively, on a computer-aided comparison of pharmacophoric patterns and on topological similarity. The structure-activity relationships are discussed in light of both similarity concepts. Compound 40, an N-methyl-3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decyl)acetamide derivative, designed by combining the structure-activity relationships enlightened by each method, has a subnanomolar affinity for μ (h) receptor (IC50=0.9 nM). It is a promising lead, allowing the design of a new series of analogues substituted at the N-3 of the spirocycle moiety.

Pyrrolidine modulators of chemokine receptor activity

The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, R14and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

Dipeptides which promote release of growth hormone

Compounds of formula (I) are growth hormone releasing peptide mimetics which are useful for the treatment and prevention of osteoporosis. STR1